Zobrazeno 1 - 2
of 2
pro vyhledávání: '"radiolabeled cetuximab conjugates"'
Autor:
Wiebke Sihver, Jens Pietzsch, Mechthild Krause, Michael Baumann, Jörg Steinbach, Hans-Jürgen Pietzsch
Publikováno v:
Pharmaceuticals, Vol 7, Iss 3, Pp 311-338 (2014)
The epidermal growth factor receptor (EGFR) has evolved over years into a main molecular target for the treatment of different cancer entities. In this regard, the anti-EGFR antibody cetuximab has been approved alone or in combination with: (a) chemo
Externí odkaz:
https://doaj.org/article/811e2bf1eabe4247b3131cadf7bfad32
Publikováno v:
Pharmaceuticals
Pharmaceuticals, Vol 7, Iss 3, Pp 311-338 (2014)
Pharmaceuticals 7(2014)3, 311-338
Pharmaceuticals, Vol 7, Iss 3, Pp 311-338 (2014)
Pharmaceuticals 7(2014)3, 311-338
The epidermal growth factor receptor (EGFR) has evolved over years into a main molecular target for the treatment of different cancer entities. In this regard, the anti-EGFR antibody cetuximab has been approved alone or in combination with: (a) chemo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::e2dc443a5e55cb64571e4554e11efa0c
http://europepmc.org/articles/PMC3978494
http://europepmc.org/articles/PMC3978494